文献速递其他结缔组织病

英国与美国成人及青少年起病抗TIF1γ阳性肌炎患者中抗Sp4和抗CCAR1自身抗体的比较

Anti-Sp4 and anti-CCAR1 autoantibodies in UK vs US patients with adult and juvenile-onset anti-TIF1γ-positive myositis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该研究采用酶联免疫吸附试验(ELISA)检测51例英国成人起病特发性炎症性肌病(IIM)和55例英国青少年皮肌炎(JDM)患者(均为抗TIF1γ抗体阳性)及24例健康对照的血清抗Sp4和抗CCAR1抗体。英国成人患者中抗Sp4频率为4%(2/51)、抗CCAR1为16%(8/51),均低于美国已发表数据(32%和43%)。英国青少年患者中未检测到抗Sp4,抗CCAR1频率为13%(7/55)。

要点

  • 英国成人抗TIF1γ阳性IIM中抗Sp4频率4%(2/51)、抗CCAR1频率16%(8/51),均低于美国报道的32%和43%。
  • 英国青少年抗TIF1γ阳性JDM中抗Sp4未检出,抗CCAR1频率13%(7/55),与美国报道的9%和19%相比抗Sp4更低而抗CCAR1相似。
  • 37%(19/51)英国成人患者合并肿瘤,2例抗Sp4阳性者均无肿瘤,25%(2/8)抗CCAR1阳性者合并肿瘤,未发现抗Sp4或抗CCAR1的临床关联。

核心结论

  • 抗Sp4和抗CCAR1自身抗体在英国成人抗TIF1γ阳性肌炎人群中较美国已发表数据少见,限制了其作为肿瘤风险生物标志物的应用。
  • 在青少年起病患者中,英国抗Sp4频率低于美国,但抗CCAR1抗体患病率相似。

研究设计与样本

  • 研究采用ELISA法筛查51例英国成人起病IIM患者、55例英国JDM患者(均为抗TIF1γ自身抗体阳性)及24例健康对照血清中的抗Sp4和抗CCAR1自身抗体。

主要发现

  • 英国成人抗TIF1γ阳性IIM患者中,抗Sp4频率为4%(2/51),抗CCAR1频率为16%(8/51)。
  • 2例抗Sp4阳性成人患者同时抗CCAR1阳性。
  • 英国青少年患者中未检测到抗Sp4,13%(7/55)有抗CCAR1自身抗体。
  • 19例(37%)英国成人抗TIF1γ阳性肌炎患者合并肿瘤;2例抗Sp4阳性者均无肿瘤,25%(2/8)抗CCAR1阳性患者合并肿瘤。
  • 未发现抗Sp4或抗CCAR1的临床关联。

关键数值与推荐

  • 美国抗TIF1γ阳性DM患者中,成人抗Sp4和抗CCAR1频率分别为32%和43%,青少年分别为9%和19%。
  • 英国成人抗TIF1γ阳性IIM中抗Sp4频率4%(2/51)、抗CCAR1频率16%(8/51)。
  • 英国青少年抗TIF1γ阳性JDM中抗Sp4未检出、抗CCAR1频率13%(7/55)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Anti-transcriptional intermediary factor 1γ (TIF1γ) autoantibodies are associated with malignancy in adult-onset idiopathic inflammatory myopathy (IIM) and this risk is attenuated if patients are also positive for anti-specificity protein 4 (Sp4) or anti-cell division cycle apoptosis regulator protein 1 (CCAR1). In anti-TIF1γ positive dermatomyositis (DM) patients from the USA, anti-Sp4 and anti-CCAR1 autoantibody frequencies are reported as 32% and 43% in adults and 9% and 19% in juveniles, respectively. This study aims to identify the frequency of anti-Sp4 and anti-CCAR1 in adult and juvenile UK anti-TIF1γ-positive myositis populations and report clinical associations. METHODS: Serum samples from 51 UK participants with adult-onset IIM and 55 UK participants with JDM, all anti-TIF1γ autoantibody positive, and 24 healthy control samples were screened for anti-Sp4 and anti-CCAR1 autoantibodies by ELISA. RESULTS: In UK adult anti-TIF1γ positive IIM patients, anti-Sp4 and anti-CCAR1 frequencies were 4% (2/51) and 16% (8/51). Both adult patients with anti-Sp4 were also positive for anti-CCAR1. In UK juveniles, anti-Sp4 was not detected and 13% (7/55) had anti-CCAR1 autoantibodies. Nineteen (37%) anti-TIF1γ positive UK adult myositis patients had cancer; neither of the two patients with anti-Sp4 autoantibodies and 25% (2/8) of anti-CCAR1 autoantibody-positive patients had cancer. No anti-Sp4 or anti-CCAR1 clinical associations were identified. CONCLUSION: Anti-Sp4 and anti-CCAR1 autoantibodies are less common in the adult UK anti-TIF1γ-positive myositis population compared with published data from the USA, limiting their use as biomarkers for cancer risk. In patients with juvenile onset disease, anti-Sp4 is less frequent in UK patients compared with the USA, but the prevalence of anti-CCAR1 autoantibodies is similar.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. McMorrow FK, Wedderburn LR, Chinoy H, et al. Anti-Sp4 and anti-CCAR1 autoantibodies in UK vs US patients with adult and juvenile-onset anti-TIF1γ-positive myositis. Rheumatology (Oxford). 2025. PMID: 39514366. doi:10.1093/rheumatology/keae574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。